Cullinan Management, Inc. (CGEM)
NASDAQ:CGEM
Want to see CGEM full AI Analyst Report?
Top Page
Cullinan Management
(NASDAQ:CGEM)
Select Model
Select Model
Rating:57Neutral
Price Target:
$16.50
▲(9.56% Upside)
Action:Reiterated
Date:05/19/26
The score is held back primarily by weak and deteriorating financial performance (large losses and persistent cash burn), partially offset by a low-debt balance sheet. Technicals are supportive with price above key moving averages and positive MACD, and a recent positive clinical data update improves near-term sentiment, while valuation remains constrained by negative earnings and no dividend.
Positive Factors
Low-leverage balance sheet
Cullinan's minimal debt burden materially reduces financial distress risk and preserves strategic optionality. Low leverage supports continued R&D spend and partnership talks without heavy interest costs, giving the company flexibility to fund trials or pursue collaborations across the next several quarters.
Negative Factors
Sustained high cash burn
Consistently negative operating cash flow and accelerating burn materially shorten runway absent funding or revenue inflection. Continued high cash outflows will likely necessitate financing or milestone-dependent partnerships, increasing dilution risk and constraining discretionary investment choices over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-leverage balance sheet
Cullinan's minimal debt burden materially reduces financial distress risk and preserves strategic optionality. Low leverage supports continued R&D spend and partnership talks without heavy interest costs, giving the company flexibility to fund trials or pursue collaborations across the next several quarters.
Read all positive factors
Cullinan Management (CGEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$880.69M
Dividend YieldN/A
Average Volume (3M)839.21K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue GrowthN/A
EPS Growth-19.99%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-3.75
Shares Outstanding61,458,046
10 Day Avg. Volume1,088,940
30 Day Avg. Volume839,208
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.96K
Enterprise Value/Ebitda-3.34
Forecast
1Y Price Target
$31.78Price Target Upside111.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.04
Revenue Forecast (FY)$22.32M
Cullinan Management Business Overview & Revenue Model
Company Description
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The c...
How the Company Makes Money
Cullinan Oncology generates revenue primarily through the development, commercialization, and partnership of its oncology drug candidates. The company collaborates with research organizations, licensing its proprietary technologies and intellectua...
Cullinan Management Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.94M |
| Gross Profit | -79.00K | 0.00 | -306.00K | -310.00K | 0.00 | 18.94M |
| EBITDA | -235.13M | -241.34M | -167.15M | -190.34M | -132.04M | -67.90M |
| Net Income | -221.04M | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
Balance Sheet | ||||||
| Total Assets | 402.98M | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Cash, Cash Equivalents and Short-Term Investments | 351.88M | 377.90M | 398.98M | 467.07M | 467.29M | 290.47M |
| Total Debt | 2.38M | 2.68M | 2.15M | 3.59M | 5.19M | 0.00 |
| Total Liabilities | 36.81M | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Stockholders Equity | 366.17M | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
Cash Flow | ||||||
| Free Cash Flow | -178.69M | -175.80M | -145.30M | -134.48M | -127.80M | -44.02M |
| Operating Cash Flow | -178.64M | -175.75M | -145.30M | -134.28M | -126.66M | -43.43M |
| Investing Cash Flow | 175.60M | 179.99M | -136.31M | 35.81M | 248.97M | -333.77M |
| Financing Cash Flow | 1.47M | 1.09M | 266.19M | 40.75M | -25.93M | 268.78M |
Cullinan Management Technical Analysis
Positive
15.06
Price Trends
14.20
Positive
13.32
Positive
10.75
Positive
Market Momentum
0.25
Positive
47.54
Neutral
29.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Positive. The current price of 15.06 is above the 20-day moving average (MA) of 14.43, above the 50-day MA of 14.20, and above the 200-day MA of 10.75, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 47.54 is Neutral, neither overbought nor oversold. The STOCH value of 29.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGEM.
Cullinan Management Risk Analysis
Cullinan Management disclosed 79 risk factors in its most recent earnings report. Cullinan Management reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cullinan Management Peers Comparison
UnderperformOutperform
Sector (51)
CGEM
Cullinan Management
13.98
6.09
77.19%
RNTX
Rein Therapeutics
1.04
-0.90
-46.39%
NEUP
Neuphoria Therapeutics
5.12
-1.11
-17.82%
Cullinan Management Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cullinan Management Shares Promising Early CLN-978 Autoimmune Data
Positive
May 18, 2026
On May 18, 2026, Cullinan Therapeutics reported initial clinical data from two ongoing Phase 1 OUTRACE trials of CLN-978 in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus. As of a January 14, 2026 cut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.